|
TOP NEWS
ImmunityBio Stockholder Targets Soon-Shiong In Chancery
By Jarek Rutz
The Delaware Chancery Court on Tuesday heard arguments over whether biotech billionaire Patrick Soon-Shiong and ImmunityBio Inc.'s board breached their fiduciary duties by approving insider financing that allegedly allowed him to secure equity at deeply discounted prices as the company neared regulatory approval for its lead cancer drug.
4 documents attached |
Read full article »
| Save to favorites »
LITIGATION
PEOPLE
EXPERT ANALYSIS
Upshot Of 'Skinny Label' Case May Go Beyond Pharma
The U.S. Supreme Court's pending review of Hikma v. Amarin, over a drugmaker's "skinny label," carries implications for both generics and brand-name pharmaceutical manufacturers, and could shed light on how inducement doctrine should operate in other regulated industries where products have substantial lawful uses, says Jason Shull at Banner Witcoff.
Read full article »
| Save to favorites »
LEGAL INDUSTRY
|